Eikon Therapeutics Inc EIKN
$11.39 $0.64 (5.95%) 1D
Last Updated: Aug 21, 12:00 AM·NASDAQ
Pricing for US stocks is delayed by 24 hours
EIKN Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, Eikon Therapeutics Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Eikon Therapeutics Inc. Stock Analysis EIKN
United States Health Care Small Cap Eikon Therapeutics is a biopharmaceutical company. The company is headquartered in Millbrae, California and currently employs 384 full-time employees. The company went IPO on 2026-02-05. The firm has clinical programs at various stages of development, and active discovery efforts in oncology and neurological disease. Its pipeline includes EIK1001 TLR7/8 Melanoma, EIK1001 TLR7/8 NSCLC, EIK1003 PARP1, EIK1004 PARP1, EIK1005 WRN Phase 1, EIK1006, and AR-V7. EIK1001 is a systemically administered dual-agonist of toll-like receptors 7 and 8 that has demonstrated single-agent activity, as well as activity in combination with anti-PD-(L)1 agents, across multiple solid tumor types in Phase 1 trials. EIK1003 targets PARP1, a central component of DNA repair machinery in normal cells. EIK1003 is being evaluated in a Phase 1/2 study of patients with breast, ovarian, or prostate malignancies that have known or suspected deleterious mutations of select homologous recombination repair (HRR) genes.
Eikon Therapeutics Inc (EIKN) Chart
Financial Metrics & Statements of Eikon Therapeutics Inc (EIKN)
FAQ's for Eikon Therapeutics Inc (EIKN)
- As of August 2026, Eikon Therapeutics Inc EIKN is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Eikon Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Eikon Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Eikon Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Eikon Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Eikon Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Eikon Therapeutics Inc (EIKN)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
